3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Genitourinary
1
Conditions
Multiple Myeloma
31
Recurrence
4
Renal Insufficiency
1
Kidney Failure, Chronic
1
Immunoglobulin Light-chain Amyloidosis
1
Amyloidosis
1
Interventions
Dexamethasone
4
pomalidomide
2
Azacitidine
2
vinflunine
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pevonedistat
1
pembrolizumab
1
osimertinib
1
mirabegron
1
melflufen
1
gallium 68 PSMA-11
1
copanlisib
1
carfilzomib
1
belinostat
1
belantamab mafodotin
1
Zoledronic Acid
1
Topotecan
1
Tablets
1
Sitagliptin Phosphate
1
Pluvicto
1
Paclitaxel
1
Lenalidomide
1
L-melphalanyl-p-L-fluorophenylalanine ethyl ester
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Renal Insufficiency
×
belantamab mafodotin
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled